Qualigen Therapeutics Files 8-K with Corporate Updates
Ticker: AIXC · Form: 8-K · Filed: Nov 17, 2025 · CIK: 1460702
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
Qualigen Therapeutics filed an 8-K on Nov 12, 2025, reporting corporate changes and shareholder votes.
AI Summary
Qualigen Therapeutics, Inc. filed an 8-K on November 17, 2025, reporting events that occurred on November 12, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote of security holders, and other events, along with financial statements and exhibits. The company, formerly Ritter Pharmaceuticals Inc., is incorporated in Delaware and has its principal executive offices in Carlsbad, California.
Why It Matters
This 8-K filing signals potential changes in Qualigen Therapeutics' corporate structure or governance, which could impact its strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- November 12, 2025 (date) — Date of earliest event reported
- November 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- Carlsbad, California (location) — Address of Principal Executive Offices
- Ritter Pharmaceuticals Inc. (company) — Former Company Name
FAQ
What specific amendments were made to Qualigen Therapeutics' Articles of Incorporation or Bylaws?
The filing indicates amendments were made, but the specific details of these amendments are not provided in the provided text excerpt.
What matters were submitted to a vote of Qualigen Therapeutics' security holders?
The filing states that matters were submitted to a vote, but the specific proposals or resolutions are not detailed in the provided text.
What are the 'Other Events' reported in this 8-K filing?
The filing mentions 'Other Events' as a category, but the nature of these events is not specified in the excerpt.
When was Qualigen Therapeutics, Inc. formerly known as Ritter Pharmaceuticals Inc.?
The date of the name change from Ritter Pharmaceuticals Inc. to Qualigen Therapeutics, Inc. was April 2, 2009.
What is the principal business address of Qualigen Therapeutics, Inc.?
The principal executive offices are located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
Filing Stats: 1,018 words · 4 min read · ~3 pages · Grade level 11.8 · Accepted 2025-11-17 06:10:26
Key Financial Figures
- $0.001 — h registered: Common Stock (par value $0.001 per shares) QLGN The Nasdaq Stock M
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex3-1.htm (EX-3.1) — 8KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001493152-25-023728.txt ( ) — 246KB
- qlgn-20251112.xsd (EX-101.SCH) — 3KB
- qlgn-20251112_lab.xml (EX-101.LAB) — 33KB
- qlgn-20251112_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. Item 8.01 Other Events. On November 16, 2025, the Company issued a press release announcing the name and symbol change and other business updates. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference. Item 9.01 Financial (d) Exhibit Number Description 3.1 Certification of Amendment to Certificate of Incorporation 99.1 Press Release dated November 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: November 17, 2025 By: /s/ Kevin A. Richardson II Name: Kevin A. Richardson II Title: Co-Chief Executive Officer